Latest Breaking News On - Bezuclastinib clinical development - Page 1 : comparemela.com

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting - Cogent Biosciences (NASDAQ:COGT)

Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior treatment Encouraging long-term safety and

United statesAndrew robbinsAndrew wagnerChristi waarichAlliance for researchCogent biosciences incCogent research teamLife raft groupAmerican society of clinical oncologyHarvard medical schoolBezuclastinib clinical developmentDana farber cancer instituteDana farber cancerGastrointestinal stromal tumorsAmerican societyClinical oncology

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesChristi waarichseniorAndrew robbinsFrank siebenhaarCogent biosciences incData monitoring committeeBezuclastinib clinical developmentCogent research teamHead university outpatient clinicInstitute of allergologyTotal symptom scoreAllergy asthmaImmunology annual meetingChief executiveReported outcomesMastocytosis symptom severity daily diary

Cogent Biosciences (COGT) Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Cogent Biosciences (COGT) Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrank siebenhaarAndrew robbinsHead university outpatient clinicData monitoring committeeCogent biosciences incBezuclastinib clinical developmentInstitute of allergologyCogent biosciencesAllergy asthmaImmunology annual meetingChief executivePatient reported outcomesMastocytosis symptom severity daily diaryMast cell quality of lifeClinical development based

Cogent Biosciences Announces Positive Part 1b Data from

Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based.

United statesAndrew robbinsFrank siebenhaarChristi waarichData monitoring committeeHead university outpatient clinicCogent biosciences incBezuclastinib clinical developmentCogent research teamInstitute of allergologyTotal symptom scoreAllergy asthmaImmunology annual meetingChief executivePatient reported outcomesMastocytosis symptom severity daily diary

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAndrew robbinsChristi waarichFrank siebenhaarCogent research teamData monitoring committeeCogent biosciences incBezuclastinib clinical developmentInstitute of allergologyHead university outpatient clinicBiosciences announces positive partEvaluating bezuclastinibNonadvanced systemicTotal symptom scoreAllergy asthmaImmunology annual meeting